Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience()

por Macklin, Grace R., Peak, Corey, Eisenhawer, Martin, Kurji, Feyrouz, Mach, Ondrej, Konz, John, Gast, Chris, Bachtiar, Novilia Sjafri, Bandyopadhyay, Ananda S., Zipursky, Simona
Publicado 2023

Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021

por Mirzoev, Azamdzhon, Macklin, Grace R, Zhang, Yiting, Mainou, Bernardo A, Sadykova, Umeda, Olsavszky, Victor Stefan, Huseynov, Shahin, Ruziev, Murodali, Saidzoda, Faizali, Bobokhonova, Mahtob, Mach, Ondrej
Publicado 2022

Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey

por Kennedy, Stephen B, Macklin, Grace R, Mason Ross, Gloria, Lopez Cavestany, Rocio, Moukom, Richelot A, Jones, Kathryn A V, Mainou, Bernardo A, Massaquoi, Moses B F, Kieh, Mark W S, Mach, Ondrej
Publicado 2023